Not yet recruiting NCT06977412

The Application Value of Spectral CT in the Accurate Staging of Breast Cancer

No phase Interventional Breast Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: To explore the value of spectral CT in the diagnosis and treatment of breast cancer.
Who it may be relevant to: Registry conditions: Breast Adenocarcinoma. Basic parameters: 18 years — 80 years · Female.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Center list to be confirmed — check the primary protocol.
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Spectral CT was used to prospectively collect medical images and clinical data related to breast cancer, evaluate the effect of image quality in the diagnosis of breast cancer, and evaluate the application value in the accurate staging of breast cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Interventions

Diagnostic test To explore the value of spectral CT in the diagnosis and treatment of breast cancer
The CT scan is part of the standard treatment protocol.

Primary outcome measures

Pathological TNM staging [Time frame: 1 day]

Eligibility criteria

Inclusion criteria

(a) Chest quark energy spectrum CT examination was performed within 1 week before treatment
(b) Age ≥ 18
(c) Suspected breast cancer patients
(d) Patients who signed informed consent

Exclusion criteria

(a) Severe cardiac, pulmonary and renal insufficiency
(b) Allergic to iodine contrast media
(c) Unable to cooperate to complete CT examination
(d) Quark spectrum CT image is poor and cannot be used
(e) Male, pregnant and lactating female
(f) Combined with other tumor history
(g) Incomplete clinical and pathological data
(h) Pathologically confirmed non breast cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation: N/A
Model: Single group
Masking: Open label
Primary purpose: Diagnostic

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06977412 · KYLX2025-105

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗